Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (preprint)
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2021 |
| Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/47927 |
Resumo: | This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. |
| id |
CRUZ_291241fcc5860b8661cef9c71f4d83ac |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/47927 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Liu, ChangGinn, Helen M.Dejnirattisai, WanwisaSupasa, PiyadaWang, BeibeiTuekprakhon, AekkachaiNutalai, RungtiwaZhou, DamingMentzer, Alexander J.Zhao, YuguangDuyvesteyn, Helen M.E.López-Camacho, CésarSlon-Campos, JoseWalter, Thomas S.Skelly, DonalJohnson, Sile AnnRitter, Thomas G.Mason, ChrisClemens, Sue Ann CostaNaveca, Felipe GomesNascimento, ValdineteNascimento, FernandaCosta, Cristiano Fernandes daResende, Paola CristinaPauvolid- Correa, AlexSiqueira, Marilda Agudo Mendonça Teixeira deDold, ChristinaTemperton, NigelDong, TaoPollard, Andrew J.Knight, Julian C.Crook, DerrickLambe, TeresaClutterbuck, ElizabethBibi, SagidaFlaxman, AmyBittaye, MustaphaBelij- Rammerstorfer, SandraGilbert, Sarah C.Malik, TariqCarroll, Miles W.Klenerman, PaulBarnes, EleanorDunachie, Susanna J.Baillie, VickySerafin, NataliDitse, ZaneleSilva, Kelly daPaterson, Neil G.Williams, Mark A.Hall, David R.Madhi, ShabirNunes, Marta C.Goulder, PhilipFry, Elizabeth E.Mongkolsapaya, JuthathipRen, JingshanStuart, David I.Screaton, Gavin R.2021-06-30T14:02:47Z2021-06-30T14:02:47Z2021LIU, Chang et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell, p. 1-74, 25 Maio. 2021.https://www.arca.fiocruz.br/handle/icict/4792710.1016/j.cell.2021.06.020This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.A pesquisa aponta que o soro de pessoas previamente infectadas por outras cepas é menos potente contra esta variante viral. O problema é observado de forma marcante entre os indivíduos anteriormente infectados pela variante Gama, identificada originalmente em Manaus e atualmente dominante no Brasil, assim como pela variante Beta, detectada pela primeira vez na África do Sul. Nestes casos, a capacidade de neutralizar a cepa Delta é onze vezes menor. O soro de pessoas vacinadas também tem potência reduzida contra a variante originária da Índia, mas os dados apontam que as vacinas continuam efetivas. A capacidade de neutralizar a cepa é 2,5 vezes menor para o imunizante da Pfizer e 4,3 vezes menor para o da Astrazeneca. Os autores do trabalho ressaltam que os índices são semelhantes aos verificados com as variantes Gama e Alfa – que emergiram no Brasil e no Reino Unido, respectivamente. Não há evidência de fuga generalizada da neutralização, diferentemente do registrado com a variante Beta – com origem na África do Sul.SARS-CoV-2 has undergone progressive change with variants conferring advantage rapidly becoming dominant lineages e.g. B.1.617. With apparent increased transmissibility variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the UK. Here we study the ability of monoclonal antibodies, convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2 and complement this with structural analyses of Fab/RBD complexes and map the antigenic space of current variants. Neutralization of both viruses is reduced when compared with ancestral Wuhan related strains but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2 suggesting that individuals previously infected by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insight for immunisation policy with future variant vaccines in non-immune populations.University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK / University of Oxford. Oxford Institute (COI). Chinese Academy of Medical Science (CAMS). Oxford, UK.Diamond Light Source Ltd, Harwell Science & Innovation Campus. Didcot, UK.University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK.University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK.University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK.University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK.University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK.University of Oxford. Centre for Human Genetics. Division of Structural Biology, Nuffield Department of Medicine. Oxford, UK.University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK / Oxford University Hospitals NHS Foundation Trust, Oxford, UK.University of Oxford. Centre for Human Genetics. Division of Structural Biology, Nuffield Department of Medicine. Oxford, UK.University of Oxford. Centre for Human Genetics. Division of Structural Biology, Nuffield Department of Medicine. Oxford, UK.University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK.University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK.University of Oxford. Centre for Human Genetics. Division of Structural Biology, Nuffield Department of Medicine. Oxford, UK.Oxford University Hospitals NHS Foundation Trust, Oxford, UK / Peter Medawar Building for Pathogen Research, Oxford, UK / University of Oxford. Nuffield Department of Clinical Neurosciences. Oxford, UK.Peter Medawar Building for Pathogen Research, Oxford, UK.Oxford University Hospitals NHS Foundation Trust, Oxford, UK.Oxford University Hospitals NHS Foundation Trust, Oxford, UK.University of Siena. Institute of Global Health. Siena, Brazil / University of Oxford. Department of Paediatrics. Oxford, UK.Fundação Oswaldo Cruz. Fiocruz Amazônia. Instituto Leônidas e Maria Deane. Laboratório de Ecologia de Doenças Transmissíveis na Amazônia. Manaus, AM, Brasil.Fundação Oswaldo Cruz. Fiocruz Amazônia. Instituto Leônidas e Maria Deane. Laboratório de Ecologia de Doenças Transmissíveis na Amazônia. Manaus, AM, Brasil.Fundação Oswaldo Cruz. Fiocruz Amazônia. Instituto Leônidas e Maria Deane. Laboratório de Ecologia de Doenças Transmissíveis na Amazônia. Manaus, AM, Brasil.Fundação de Vigilância em Saúde do Amazonas. Manaus, Amazonas, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de vírus respiratórios. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de vírus respiratórios. Rio de Janeiro, RJ, Brasil / Texas University. College Station. Department of Veterinary Integrative Biosciences. Texas, TX, United States.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de vírus respiratórios. Rio de Janeiro, RJ, Brasil.NIHR Oxford Biomedical Research Centre. Oxford, UK / University of Oxford. Oxford Vaccine Group. Department of Paediatrics. Oxford, UK.University of Kent and Greenwich. Medway School of Pharmacy. Viral Pseudotype Unit. Chatham Maritime, Kent ME4 4TB, UK.University of Oxford. Oxford Institute (COI). Chinese Academy of Medical Science (CAMS). Oxford, UK / University of Oxford. Nuffield Department of Medicine. Oxford, UK / University of Oxford. MRC Weatherall Institute of Molecular Medicine. MRC Human Immunology Unit. Radcliffe Department of Medicine. Oxford, UK.NIHR Oxford Biomedical Research Centre, Oxford, UK / Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.NIHR Oxford Biomedical Research Centre, Oxford, UK / Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK / National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.Oxford University Hospitals NHS Foundation Trust, Oxford, UK / Peter Medawar Building for Pathogen Research, Oxford, UK / NIHR Oxford Biomedical Research Centre, Oxford, UK / Translational Gastroenterology Unit, University of Oxford, Oxford, UK.Oxford University Hospitals NHS Foundation Trust, Oxford, UK / Peter Medawar Building for Pathogen Research, Oxford, UK / NIHR Oxford Biomedical Research Centre, Oxford, UK / Translational Gastroenterology Unit, University of Oxford, Oxford, UK.Oxford University Hospitals NHS Foundation Trust, Oxford, UK / Peter Medawar Building for Pathogen Research, Oxford, UK / Centre For Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK / Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand, Department of Medicine, University of Oxford, Oxford, UK.South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa / Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaDepartment of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaDepartment of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaDepartment of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaDiamond Light Source Ltd, Harwell Science & Innovation Campus. Didcot, UK.Diamond Light Source Ltd, Harwell Science & Innovation Campus. Didcot, UK.South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa / Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa / Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.Peter Medawar Building for Pathogen Research, Oxford, UK.Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK / Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK / Siriraj Center of Research Excellence in Dengue & Emerging Pathogens, Dean Office for Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand.Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK / Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK / Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK / Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK / Instruct-ERIC, Oxford House, Parkway Court, John Smith Drive, Oxford, UK.Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK / Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.engElsevierhttps://www.arca.fiocruz.br/handle/icict/51604COVID-19SARS-CoV-2ReinfecçãoVariante DeltaCOVID-19SARS-CoV-2VaccineConvalescent serumReduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (preprint)info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleSimPublicadoinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83128https://www.arca.fiocruz.br/bitstream/icict/47927/1/license.txt0a01a23320286399b52cf17eb1aafb12MD51ORIGINALReduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.pdfReduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.pdfapplication/pdf8847138https://www.arca.fiocruz.br/bitstream/icict/47927/2/Reduced%20neutralization%20of%20SARS-CoV-2%20B.1.617%20by%20vaccine%20and%20convalescent%20serum.pdf1ff8616646f32257d4e7a8e869e0c15eMD52TEXTReduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.pdf.txtReduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.pdf.txtExtracted texttext/plain118422https://www.arca.fiocruz.br/bitstream/icict/47927/3/Reduced%20neutralization%20of%20SARS-CoV-2%20B.1.617%20by%20vaccine%20and%20convalescent%20serum.pdf.txt675e3ecc8b2742e067995345375dd079MD53icict/479272022-03-25 22:36:12.718oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-03-26T01:36:12Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (preprint) |
| title |
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (preprint) |
| spellingShingle |
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (preprint) Liu, Chang COVID-19 SARS-CoV-2 Reinfecção Variante Delta COVID-19 SARS-CoV-2 Vaccine Convalescent serum |
| title_short |
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (preprint) |
| title_full |
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (preprint) |
| title_fullStr |
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (preprint) |
| title_full_unstemmed |
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (preprint) |
| title_sort |
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (preprint) |
| author |
Liu, Chang |
| author_facet |
Liu, Chang Ginn, Helen M. Dejnirattisai, Wanwisa Supasa, Piyada Wang, Beibei Tuekprakhon, Aekkachai Nutalai, Rungtiwa Zhou, Daming Mentzer, Alexander J. Zhao, Yuguang Duyvesteyn, Helen M.E. López-Camacho, César Slon-Campos, Jose Walter, Thomas S. Skelly, Donal Johnson, Sile Ann Ritter, Thomas G. Mason, Chris Clemens, Sue Ann Costa Naveca, Felipe Gomes Nascimento, Valdinete Nascimento, Fernanda Costa, Cristiano Fernandes da Resende, Paola Cristina Pauvolid- Correa, Alex Siqueira, Marilda Agudo Mendonça Teixeira de Dold, Christina Temperton, Nigel Dong, Tao Pollard, Andrew J. Knight, Julian C. Crook, Derrick Lambe, Teresa Clutterbuck, Elizabeth Bibi, Sagida Flaxman, Amy Bittaye, Mustapha Belij- Rammerstorfer, Sandra Gilbert, Sarah C. Malik, Tariq Carroll, Miles W. Klenerman, Paul Barnes, Eleanor Dunachie, Susanna J. Baillie, Vicky Serafin, Natali Ditse, Zanele Silva, Kelly da Paterson, Neil G. Williams, Mark A. Hall, David R. Madhi, Shabir Nunes, Marta C. Goulder, Philip Fry, Elizabeth E. Mongkolsapaya, Juthathip Ren, Jingshan Stuart, David I. Screaton, Gavin R. |
| author_role |
author |
| author2 |
Ginn, Helen M. Dejnirattisai, Wanwisa Supasa, Piyada Wang, Beibei Tuekprakhon, Aekkachai Nutalai, Rungtiwa Zhou, Daming Mentzer, Alexander J. Zhao, Yuguang Duyvesteyn, Helen M.E. López-Camacho, César Slon-Campos, Jose Walter, Thomas S. Skelly, Donal Johnson, Sile Ann Ritter, Thomas G. Mason, Chris Clemens, Sue Ann Costa Naveca, Felipe Gomes Nascimento, Valdinete Nascimento, Fernanda Costa, Cristiano Fernandes da Resende, Paola Cristina Pauvolid- Correa, Alex Siqueira, Marilda Agudo Mendonça Teixeira de Dold, Christina Temperton, Nigel Dong, Tao Pollard, Andrew J. Knight, Julian C. Crook, Derrick Lambe, Teresa Clutterbuck, Elizabeth Bibi, Sagida Flaxman, Amy Bittaye, Mustapha Belij- Rammerstorfer, Sandra Gilbert, Sarah C. Malik, Tariq Carroll, Miles W. Klenerman, Paul Barnes, Eleanor Dunachie, Susanna J. Baillie, Vicky Serafin, Natali Ditse, Zanele Silva, Kelly da Paterson, Neil G. Williams, Mark A. Hall, David R. Madhi, Shabir Nunes, Marta C. Goulder, Philip Fry, Elizabeth E. Mongkolsapaya, Juthathip Ren, Jingshan Stuart, David I. Screaton, Gavin R. |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Liu, Chang Ginn, Helen M. Dejnirattisai, Wanwisa Supasa, Piyada Wang, Beibei Tuekprakhon, Aekkachai Nutalai, Rungtiwa Zhou, Daming Mentzer, Alexander J. Zhao, Yuguang Duyvesteyn, Helen M.E. López-Camacho, César Slon-Campos, Jose Walter, Thomas S. Skelly, Donal Johnson, Sile Ann Ritter, Thomas G. Mason, Chris Clemens, Sue Ann Costa Naveca, Felipe Gomes Nascimento, Valdinete Nascimento, Fernanda Costa, Cristiano Fernandes da Resende, Paola Cristina Pauvolid- Correa, Alex Siqueira, Marilda Agudo Mendonça Teixeira de Dold, Christina Temperton, Nigel Dong, Tao Pollard, Andrew J. Knight, Julian C. Crook, Derrick Lambe, Teresa Clutterbuck, Elizabeth Bibi, Sagida Flaxman, Amy Bittaye, Mustapha Belij- Rammerstorfer, Sandra Gilbert, Sarah C. Malik, Tariq Carroll, Miles W. Klenerman, Paul Barnes, Eleanor Dunachie, Susanna J. Baillie, Vicky Serafin, Natali Ditse, Zanele Silva, Kelly da Paterson, Neil G. Williams, Mark A. Hall, David R. Madhi, Shabir Nunes, Marta C. Goulder, Philip Fry, Elizabeth E. Mongkolsapaya, Juthathip Ren, Jingshan Stuart, David I. Screaton, Gavin R. |
| dc.subject.other.pt_BR.fl_str_mv |
COVID-19 SARS-CoV-2 Reinfecção Variante Delta |
| topic |
COVID-19 SARS-CoV-2 Reinfecção Variante Delta COVID-19 SARS-CoV-2 Vaccine Convalescent serum |
| dc.subject.en.pt_BR.fl_str_mv |
COVID-19 SARS-CoV-2 Vaccine Convalescent serum |
| description |
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. |
| publishDate |
2021 |
| dc.date.accessioned.fl_str_mv |
2021-06-30T14:02:47Z |
| dc.date.available.fl_str_mv |
2021-06-30T14:02:47Z |
| dc.date.issued.fl_str_mv |
2021 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
LIU, Chang et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell, p. 1-74, 25 Maio. 2021. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/47927 |
| dc.identifier.doi.pt_BR.fl_str_mv |
10.1016/j.cell.2021.06.020 |
| identifier_str_mv |
LIU, Chang et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell, p. 1-74, 25 Maio. 2021. 10.1016/j.cell.2021.06.020 |
| url |
https://www.arca.fiocruz.br/handle/icict/47927 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.hasversion.pt_BR.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/51604 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Elsevier |
| publisher.none.fl_str_mv |
Elsevier |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/47927/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/47927/2/Reduced%20neutralization%20of%20SARS-CoV-2%20B.1.617%20by%20vaccine%20and%20convalescent%20serum.pdf https://www.arca.fiocruz.br/bitstream/icict/47927/3/Reduced%20neutralization%20of%20SARS-CoV-2%20B.1.617%20by%20vaccine%20and%20convalescent%20serum.pdf.txt |
| bitstream.checksum.fl_str_mv |
0a01a23320286399b52cf17eb1aafb12 1ff8616646f32257d4e7a8e869e0c15e 675e3ecc8b2742e067995345375dd079 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813009220542398464 |